


## B. Claims

Please amend claims 17-18 as follows. The following is a complete listing of the claims in this application and replaces all earlier versions and all earlier listings of the claims.

1. (Previously Presented) A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C<sub>2</sub>-C<sub>4</sub> alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C<sub>1</sub>-C<sub>4</sub> alkyl group;

W is CO<sub>2</sub>H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen.

2. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

- 2-{{(2,4-dichlorophenoxy)acetyl}amino}benzoic acid;
- 2-{{(2,5-dimethylphenoxy)acetyl}amino}benzoic acid;
- 2-{{(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl}amino}benzoic acid;
- 2-{{(2-bromo-5-fluorophenoxy)acetyl}amino}benzoic acid;
- 2-{{(2-methyl-5-nitrophenoxy)acetyl}amino}benzoic acid;
- 2-{{(2-fluoro-5-methylphenoxy)acetyl}amino}benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;
- 2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;
- 2-{{(3-chlorophenoxy)acetyl}amino}benzoic acid;
- 2-{{(3-chlorophenoxy)acetyl}amino}-5-fluorobenzoic acid;
- 2-{{(3-chlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
- 2-{{(3,4-dimethylphenoxy)acetyl}amino}-5-hydroxybenzoic acid;
- 2-{{(3-bromophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
- 2-{{(2S)-2-(4-chlorophenoxy)propanoyl}amino}benzoic acid;
- 2-{{(2,3-dichlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
- 2-{{(2,4,5-trichlorophenoxy)acetyl}amino}benzoic acid;

2-{{(2,4-dibromophenoxy)acetyl}amino}benzoic acid;  
 2-{{(2-chlorophenoxy)acetyl}amino}benzoic acid;  
 2-{{N-(3-bromophenyl)glycyl}amino}benzoic acid;  
 2-{{N-(4-bromo-3-chlorophenyl)-N-methylglycyl}amino}benzoic  
 acid;  
  
 2-{{(4-chloro-2-methylphenoxy)acetyl}amino}benzoic acid;  
 2-{{(5-chloro-2-methylphenoxy)acetyl}amino}benzoic acid;  
 2-{{(3,4-difluorophenoxy)acetyl}amino}benzoic acid;  
 2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;  
 2-{{N-(3,4-dibromophenyl)-N-methylglycyl}amino}benzoic acid;  
 2-{{N-(2,5-dibromophenyl)glycyl}amino}benzoic acid;  
 2-{{(2-cyanophenoxy)acetyl}amino}benzoic acid;  
 5-hydroxy-2-{{(2,4,5-trichlorophenoxy)acetyl}amino}benzoic acid;  
 2-{{(2-chloro-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;  
 2-{{[4-chloro-3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic  
 acid;  
  
 2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}benzoic  
 acid;  
  
 2-{{(2-ethyl-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;  
 2-{{[(3,4-dichlorophenyl)sulfanyl]acetyl}amino}benzoic acid;  
 2-{{[(4-chlorophenyl)sulfanyl]acetyl}amino}benzoic acid;  
 2-{{(2-bromo-4,5-difluorophenoxy)acetyl}amino}benzoic acid;  
 2-{{[3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;

2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2,4,5-trifluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3,5-dichlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{((2,4,5-trichlorophenyl)thio)acetyl}amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid};

2-{{(3,5-difluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3,5-difluorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2-bromophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2-chloro-6-methylphenoxy)acetyl}amino}benzoic acid;

2-{{(4-chloro-3-ethylphenoxy)acetyl}amino}benzoic acid;

2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid};

5-hydroxy-2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid};

2-{{(3-chloro-4-methylphenoxy)acetyl}amino}benzoic acid;

2-{{(3-chloro-4-methylphenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2-chloro-5-fluorophenoxy)acetyl}amino}benzoic acid;

2-{{(2-chloro-5-fluorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(3-chloro-4-fluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3-chloro-4-fluorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(4-chloro-3-fluorophenoxy)acetyl}amino}benzoic acid;

2- {[N-(3,4-difluorophenyl)glycyl]amino} benzoic acid;  
2- {[N-(3,4-dichlorophenyl)glycyl]amino} benzoic acid;  
2- {[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
2- {[N-(4-chloro-2-fluorophenyl)glycyl]amino} benzoic acid;  
2- {[[(4-chloro-3-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic  
acid;

2- {[N-(2-fluoro-4-methylphenyl)glycyl]amino} benzoic acid;  
2- {[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
2- {[N-(2,5-dichlorophenyl)glycyl]amino} benzoic acid;  
2- {[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
2- {[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino} benzoic acid;  
2- {[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-  
hydroxybenzoic acid;

2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino} benzoic acid;  
2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-  
hydroxybenzoic acid;

2- {[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-  
hydroxybenzoic acid;

2- {[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-  
hydroxybenzoic acid;

2- {[N-(3-chloro-4-fluorophenyl)glycyl]amino} benzoic acid;  
2- {[[(3,4,-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
2- {[[(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-bromo-4-methylphenoxy)acetyl]amino}benzoic acid;  
2-{[(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
2-{[2-(2-chloro-phenoxy)acetyl]amino}benzoic acid;  
2-[{(4-bromophenyl)methyl}{2-isopropyl-5-methylphenoxyacetyl}amino]benzoic acid;  
2-{[(4-cyclohexylphenoxy)acetyl]amino}benzoic acid; and  
pharmaceutically acceptable salts thereof.


3. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;  
2-{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
2-{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
and pharmaceutically acceptable salts thereof.

4. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

5-hydroxy-2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;  
2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

5. (Original) The method of claim 1 wherein the mammal is human.
6. (Original) The method of claim 5 wherein the composition is administered orally to said human.
7. (Original) The method of claim 6 wherein the compound is administered orally at a dose range of about 0.01 to 100 mg/kg from 1 to 6 times a day.
8. (Original) The method of claim 7 wherein the compound is administered orally at a dose range of about 0.1 to 10 mg/kg from 1 to 6 times a day.
9. (Original) The method of claim 8 wherein the compound is administered from 1 to 4 times a day.
10. (Original) The method of claim 5 wherein the composition is administered subcutaneously to said human.
11. (Previously Presented) A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C<sub>2</sub>-C<sub>4</sub> alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C<sub>1</sub>-C<sub>4</sub> alkyl group;

W is CO<sub>2</sub>H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen;

and a pharmaceutically acceptable carrier.

12. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

- 2-{{(2,4-dichlorophenoxy)acetyl}amino}benzoic acid;
- 2-{{(2,5-dimethylphenoxy)acetyl}amino}benzoic acid;
- 2-{{(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl}amino}benzoic acid;
- 2-{{(2-bromo-5-fluorophenoxy)acetyl}amino}benzoic acid;
- 2-{{(2-methyl-5-nitrophenoxy)acetyl}amino}benzoic acid;
- 2-{{(2-fluoro-5-methylphenoxy)acetyl}amino}benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;



2-[2-(4-Chloro-phenoxy)-acetyl-amino]-benzoic acid;  
 2-[2-(4-Fluoro-phenoxy)-acetyl-amino]-benzoic acid;  
 2-[[3-(chlorophenoxy)acetyl]amino}benzoic acid;  
 2-[[3-(chlorophenoxy)acetyl]amino}-5-fluorobenzoic acid;  
 2-[[3-(chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
 2-[[3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
 2-[[3-(bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
 2-[[2S)-2-(4-chlorophenoxy)propanoyl]amino}benzoic acid;  
 2-[[2,3-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
 2-[[2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;  
 2-[[2,4-dibromophenoxy)acetyl]amino}benzoic acid;  
 2-[[2-(chlorophenoxy)acetyl]amino}benzoic acid;  
 2-[N-(3-bromophenyl)glycyl]amino}benzoic acid;  
 2-[N-(4-bromo-3-chlorophenyl)-N-methylglycyl]amino}benzoic acid;  
 acid;

2-[[4-(chloro-2-methylphenoxy)acetyl]amino}benzoic acid;  
 2-[[5-(chloro-2-methylphenoxy)acetyl]amino}benzoic acid;  
 2-[[3,4-difluorophenoxy)acetyl]amino}benzoic acid;  
 2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;  
 2-[N-(3,4-dibromophenyl)-N-methylglycyl]amino}benzoic acid;  
 2-[N-(2,5-dibromophenyl)glycyl]amino}benzoic acid;  
 2-[[2-(cyanophenoxy)acetyl]amino}benzoic acid;  
 5-hydroxy-2-[[2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{{(2-chloro-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;  
2-{{(4-chloro-3-(trifluoromethyl)phenoxy)acetyl}amino}benzoic  
acid;

2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}benzoic  
acid;

2-{{(2-ethyl-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;  
2-{{(3,4-dichlorophenyl)sulfanyl}acetyl}amino}benzoic acid;  
2-{{(4-chlorophenyl)sulfanyl}acetyl}amino}benzoic acid;  
2-{{(2-bromo-4,5-difluorophenoxy)acetyl}amino}benzoic acid;  
2-{{(3-(trifluoromethyl)phenoxy)acetyl}amino}benzoic acid;  
2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}-5-  
hydroxybenzoic acid;

2-{{(2,4,5-trifluorophenoxy)acetyl}amino}benzoic acid;  
2-{{(3,5-dichlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;  
2-{{(2,4,5-trichlorophenyl)thio}acetyl}amino}benzoic acid;  
2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid;  
2-{{(3,5-difluorophenoxy)acetyl}amino}benzoic acid;  
2-{{(3,5-difluorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;  
2-{{(2-bromophenoxy)acetyl}amino}-5-hydroxybenzoic acid;  
2-{{(2-chloro-6-methylphenoxy)acetyl}amino}benzoic acid;  
2-{{(4-chloro-3-ethylphenoxy)acetyl}amino}benzoic acid;  
2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;  
5-hydroxy-2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;

2-[[3-chloro-4-methylphenoxy]acetyl]amino} benzoic acid;  
 2-[[3-chloro-4-methylphenoxy]acetyl]amino}-5-hydroxybenzoic  
 acid;

2-[[2-chloro-5-fluorophenoxy]acetyl]amino} benzoic acid;  
 2-[[2-chloro-5-fluorophenoxy]acetyl]amino}-5-hydroxybenzoic  
 acid;

2-[[3-chloro-4-fluorophenoxy]acetyl]amino} benzoic acid;  
 2-[[3-chloro-4-fluorophenoxy]acetyl]amino}-5-hydroxybenzoic  
 acid;

2-[[4-chloro-3-fluorophenoxy]acetyl]amino} benzoic acid;  
 2-[N-(3,4-difluorophenyl)glycyl]amino} benzoic acid;  
 2-[N-(3,4-dichlorophenyl)glycyl]amino} benzoic acid;  
 2-[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
 2-[N-(4-chloro-2-fluorophenyl)glycyl]amino} benzoic acid;  
 2-[[4-chloro-3-fluorophenoxy]acetyl]amino}-5-hydroxybenzoic  
 acid;

2-[N-(2-fluoro-4-methylphenyl)glycyl]amino} benzoic acid;  
 2-[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
 2-[N-(2,5-dichlorophenyl)glycyl]amino} benzoic acid;  
 2-[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
 2-[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino} benzoic acid;  
 2-[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-  
 hydroxybenzoic acid;

2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino} benzoic acid;  
 2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-  
 hydroxybenzoic acid;  
 2- {[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-  
 hydroxybenzoic acid;  
 2- {[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-  
 hydroxybenzoic acid;  
 2- {[N-(3-chloro-4-fluorophenyl)glycyl]amino} benzoic acid;  
 2- {[ (3,4,-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
 2- {[ (2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
 2- {[ (2-bromo-4-methylphenoxy)acetyl]amino} benzoic acid;  
 2- {[ (4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;  
 2- {[2-(2-chloro-phenoxy)acetyl]amino} benzoic acid;  
 2- {[ (4-bromophenyl)methyl} {2-isopropyl-5-  
 methylphenoxyacetyl} amino] benzoic acid;  
 2- {[ (4-cyclohexylphenoxy)acetyl]amino} benzoic acid, and  
 pharmaceutically acceptable salts thereof.

13. (Original) The composition of claim 11 wherein the compound is  
 selected from the group consisting of

2- {[ (2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;  
 2- {[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;  
 2- {[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

and pharmaceutically acceptable salts thereof.

14. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

5-hydroxy-2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;


2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-

hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-

hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

15. (Original) A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



(II)

and pharmaceutically acceptable salts thereof, wherein:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C<sub>2</sub>-C<sub>4</sub> alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C<sub>1</sub>-C<sub>4</sub> alkyl group;

Y is CO<sub>2</sub>H or CO<sub>2</sub>CH<sub>3</sub>;

Z is hydrogen or mono-methyl;

G<sub>1</sub> is OH, F, methoxy or hydrogen; and

G<sub>2</sub> is either OH, Cl, methoxy or hydrogen.

16. (Original) The method of claim 15 wherein the compound is selected from the group consisting of

2-[(4-chlorophenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-methoxyphenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;


2-[[3,4,-dimethylphenoxy)acetyl]amino}-4-hydroxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and

pharmaceutically acceptable salts thereof.

17. (Currently Amended) A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro,  $C_2$ - $C_4$  alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a  $C_1$ - $C_4$  alkyl group;

Y is  $CO_2H$  or  $CO_2CH_3$ ;

Z is hydrogen or mono-methyl;

$G_1$  is OH, F, methoxy or hydrogen; and

$G_2$  is either OH, Cl, methoxy or hydrogen;

and a pharmaceutically acceptable carrier.

18. (Currently Amended) The pharmaceutical composition of claim 17 wherein the compound is selected from the group consisting of

~~2-[(4-chlorophenoxy)acetylamino]benzoic acid methyl ester;~~

~~2-[(4-methoxyphenoxy)acetylamino]benzoic acid methyl ester;~~

2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;

2-{[(3,4,-dimethylphenoxy)acetyl]amino}-4-hydroxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and

pharmaceutically acceptable salts thereof.